InMode Ltd. is rated a Buy, offering strong growth, innovation, global expansion, and attractive value. Learn more about INMD ...
Fintel reports that on October 10, 2025, Canaccord Genuity maintained coverage of InMode (NasdaqGS:INMD) with a Hold recommendation. Analyst Price Forecast Suggests 8.62% Upside As of September 30, ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Miami investor is pressing an ...
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable ...
Capital Fund Management S.A. grew its holdings in shares of InMode Ltd. (NASDAQ:INMD – Free Report) by 72.3% in the 1st quarter, according to its most recent disclosure with the Securities and ...
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radio frequency ("RF") technology. InMode strives to enable ...
InMode saw 0 positive EPS revisions and 5 negative EPS revisions in the last 90 days. See InMode’s stock price’s past reactions to earnings here. According to InvestingPro, InMode’s Financial Health ...
YOKNEAM, Israel, May 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback